Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

ClinicalTrials.gov ID: NCT01427933

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01427933. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 8:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.

Study identification

NCT ID
NCT01427933
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
141 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2011 (Type not available)
Primary completion
Sep 2013 (Actual)
Completion
Jun 2014 (Actual)
Last update posted
Feb 6, 2017

2011 – 2014

United States locations

U.S. sites
52
U.S. states
24
U.S. cities
52
Facility City State ZIP Site status
ImClone Investigational Site Birmingham Alabama 35211 —
ImClone Investigational Site Gilroy California 95020 —
ImClone Investigational Site Palm Springs California 92262 —
ImClone Investigational Site Denver Colorado 80220 —
ImClone Investigational Site Southington Connecticut 06489 —
ImClone Investigational Site Fort Myers Florida 33916 —
ImClone Investigational Site Jacksonville Florida 32207 —
ImClone Investigational Site Orlando Florida 32806 —
ImClone Investigational Site Plantation Florida 33324 —
ImClone Investigational Site Port Saint Lucie Florida 34952 —
ImClone Investigational Site St. Petersburg Florida 33705 —
ImClone Investigational Site Tampa Florida 33612 —
ImClone Investigational Site Albany Georgia 31701 —
ImClone Investigational Site Lawrenceville Georgia 30046 —
ImClone Investigational Site Park Ridge Illinois 60068 —
ImClone Investigational Site Columbia Maryland 21044 —
ImClone Investigational Site Rockville Maryland 20850 —
ImClone Investigational Site Dearborn Michigan 48126 —
ImClone Investigational Site Minneapolis Minnesota 55404 —
ImClone Investigational Site Saint Joseph Missouri 64507 —
ImClone Investigational Site St Louis Missouri 63110 —
ImClone Investigational Site Henderson Nevada 89074 —
ImClone Investigational Site Morristown New Jersey 07960 —
ImClone Investigational Site Johnson City New York 13790 —
ImClone Investigational Site Lake Success New York 11042 —
ImClone Investigational Site The Bronx New York 10469 —
ImClone Investigational Site Burlington North Carolina 27215 —
ImClone Investigational Site Chapel Hill North Carolina 27599 —
ImClone Investigational Site Dayton Ohio 45429 —
ImClone Investigational Site Middletown Ohio 45042 —
ImClone Investigational Site Toledo Ohio 43623 —
ImClone Investigational Site Portland Oregon 97213 —
ImClone Investigational Site Pittsburgh Pennsylvania 15213 —
ImClone Investigational Site Charleston South Carolina 29414 —
ImClone Investigational Site Greenville South Carolina 29605 —
ImClone Investigational Site Chattanooga Tennessee 37404 —
ImClone Investigational Site Nashville Tennessee 37203 —
ImClone Investigational Site Arlington Texas 76014 —
ImClone Investigational Site Bedford Texas 76022 —
ImClone Investigational Site Dallas Texas 75246 —
ImClone Investigational Site Fort Worth Texas 76104 —
ImClone Investigational Site Houston Texas 77024 —
ImClone Investigational Site Plano Texas 75075 —
ImClone Investigational Site San Antonio Texas 78217 —
ImClone Investigational Site The Woodlands Texas 77380 —
ImClone Investigational Site Tyler Texas 75702 —
ImClone Investigational Site Rutland Vermont 05701 —
ImClone Investigational Site Fairfax Virginia 22031 —
ImClone Investigational Site Norfolk Virginia 23502 —
ImClone Investigational Site Richmond Virginia 23230 —
ImClone Investigational Site Salem Virginia 24153 —
ImClone Investigational Site Vancouver Washington 98684 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01427933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 6, 2017 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.